PMID- 26901838 OWN - NLM STAT- MEDLINE DCOM- 20160726 LR - 20181113 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 11 IP - 2 DP - 2016 TI - The Dietary Isoflavone Daidzein Reduces Expression of Pro-Inflammatory Genes through PPARalpha/gamma and JNK Pathways in Adipocyte and Macrophage Co-Cultures. PG - e0149676 LID - 10.1371/journal.pone.0149676 [doi] LID - e0149676 AB - Obesity-induced inflammation caused by adipocyte-macrophage interactions plays a critical role in developing insulin resistance, and peroxisome proliferator-activated receptors (PPARs) regulate inflammatory gene expression in these cells. Recently, the soy isoflavone daidzein was reported to act as a PPAR activator. We examined whether daidzein affected adipocyte-macrophage crosstalk via the regulation of PPARs. Co-cultures of 3T3-L1 adipocytes and RAW264 macrophages, or palmitate-stimulated RAW264 macrophages were treated with daidzein in the presence or absence of specific inhibitors for PPARs: GW6471 (a PPARalpha antagonist), and GW9662 (a PPARgamma antagonist). Inflammatory gene expression was then determined. Daidzein significantly decreased chemokine (C-C motif) ligand 2 (Ccl2, known in humans as monocyte chemo-attractant protein 1 (MCP1)) and interleukin 6 (Il6) mRNA levels induced by co-culture. In 3T3-L1 adipocytes, daidzein inversed the attenuation of adiponectin gene expression by co-culture, and these effects were inhibited by the PPAR-gamma specific inhibitor. Daidzein also decreased Ccl2 and Il6 mRNA levels in RAW264 macrophages stimulated with palmitate or conditioned medium (CM) from hypertrophied 3T3-L1 adipocytes. This inhibitory effect on Il6 expression was abrogated by a PPAR-alpha inhibitor. Additionally, we examined the activation of nuclear factor-kappa B (NF-kappaB) and c-Jun N-terminal kinase (JNK) pathways and found that daidzein significantly inhibited palmitate-induced phosphorylation of JNK. Our data suggest that daidzein regulates pro-inflammatory gene expression by activating PPAR-alpha and -gamma and inhibiting the JNK pathway in adipocyte and macrophage co-cultures. These effects might be favorable in improving adipose inflammation, thus, treatment of daidzein may be a therapeutic strategy for chronic inflammation in obese adipose tissue. FAU - Sakamoto, Yuri AU - Sakamoto Y AD - Department of Nutrition and Food Science, Graduate School of Humanities and Sciences, Ochanomizu University, Otsuka, Bunkyo-ku, Tokyo, Japan. FAU - Kanatsu, Junko AU - Kanatsu J AD - Department of Nutrition and Food Science, Graduate School of Humanities and Sciences, Ochanomizu University, Otsuka, Bunkyo-ku, Tokyo, Japan. FAU - Toh, Mariko AU - Toh M AD - Department of Nutrition and Food Science, Graduate School of Humanities and Sciences, Ochanomizu University, Otsuka, Bunkyo-ku, Tokyo, Japan. FAU - Naka, Ayano AU - Naka A AD - Laboratory of Applied Nutrition, Faculty of Human Life and Environmental Sciences, Ochanomizu University, Tokyo, Japan. FAU - Kondo, Kazuo AU - Kondo K AD - Endowed Research Department "Food for Health", Ochanomizu University, Tokyo, Japan. FAU - Iida, Kaoruko AU - Iida K AD - Department of Nutrition and Food Science, Graduate School of Humanities and Sciences, Ochanomizu University, Otsuka, Bunkyo-ku, Tokyo, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160222 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Inflammation Mediators) RN - 0 (Isoflavones) RN - 0 (PPAR alpha) RN - 0 (PPAR gamma) RN - 6287WC5J2L (daidzein) RN - EC 2.7.11.24 (JNK Mitogen-Activated Protein Kinases) SB - IM MH - 3T3-L1 Cells MH - Adipocytes/*drug effects/*metabolism MH - Animals MH - Cell Line, Tumor MH - Coculture Techniques MH - Gene Expression Regulation/*drug effects MH - Humans MH - Inflammation Mediators/metabolism MH - Isoflavones/*pharmacology MH - JNK Mitogen-Activated Protein Kinases/*metabolism MH - Macrophages/*drug effects/*metabolism MH - Mice MH - PPAR alpha/*metabolism MH - PPAR gamma/*metabolism MH - Phosphorylation MH - Signal Transduction/*drug effects PMC - PMC4763373 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2016/02/24 06:00 MHDA- 2016/07/28 06:00 PMCR- 2016/02/22 CRDT- 2016/02/23 06:00 PHST- 2015/10/06 00:00 [received] PHST- 2016/02/02 00:00 [accepted] PHST- 2016/02/23 06:00 [entrez] PHST- 2016/02/24 06:00 [pubmed] PHST- 2016/07/28 06:00 [medline] PHST- 2016/02/22 00:00 [pmc-release] AID - PONE-D-15-44009 [pii] AID - 10.1371/journal.pone.0149676 [doi] PST - epublish SO - PLoS One. 2016 Feb 22;11(2):e0149676. doi: 10.1371/journal.pone.0149676. eCollection 2016.